Peptides for tendon and ligament recovery

Tendon and ligament injuries are notoriously slow to heal. Both tissues are poorly vascularised, which means the blood supply that normally drives repair is limited. Two peptides dominate the online conversation about speeding that process: BPC-157 and TB-500. This article explains what each compound is, what the evidence actually shows, and where the gaps remain before considering either one^[1].

Why tendons and ligaments are hard to heal

Tendons connect muscle to bone; ligaments connect bone to bone. Both are dense connective tissues built mostly from type-I collagen. That density is what makes them strong, but it also means they have low cell counts (few tenocytes or fibroblasts to run the repair) and poor blood supply. Healing after a partial or full tear follows a predictable three-phase pattern: inflammation, proliferation, and remodelling. The remodelling phase alone can run for more than a year, and the collagen that fills the repair site is often scar-tissue collagen rather than the well-oriented load-bearing fibrils of the original structure.

This slow, imperfect biology is why researchers and clinicians have been interested in growth-factor and peptide-based approaches. The idea is to accelerate or improve one or more phases of the repair cascade rather than relying on the tissue's own limited resources.

BPC-157: what it is and what the research shows

BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice. The University of Zagreb group that identified it in the early 1990s has produced the majority of the published work, which consists almost entirely of rodent studies. In those models, BPC-157 appears to promote angiogenesis (the growth of new blood vessels), modulate growth-factor signalling including VEGF and FGF, and support the healing of transected Achilles tendons and medial collateral ligament injuries^[2].

A 2025 systematic review of 36 studies found that 35 were preclinical and one was a small retrospective case series of 12 patients with chronic knee pain^[2]. Seven of those twelve patients reported pain relief lasting more than six months, which is interesting but does not constitute controlled evidence. There are no published randomised controlled trials of BPC-157 for tendon or ligament repair in humans. The literature reports doses used in rodent studies in the range of 10 micrograms per kilogram to approximately 1 milligram per kilogram, but these figures have not been validated in human dose-finding trials and cannot be directly translated to a human regimen.

TB-500: what it is and what the research shows

TB-500 is a grey-market trade name used for two distinct molecules: the full-length thymosin beta-4 (Tb4), a 43-amino-acid G-actin sequestering protein first isolated from calf thymus in the 1960s, and a synthetic heptapeptide fragment covering residues 17 to 23 of Tb4 (the sequence AC-LKKTETQ). The distinction matters because most of the published research concerns full-length Tb4, while what circulates in grey-market channels is often the fragment.

Preclinical studies on Tb4 show promotion of angiogenesis, reduction of inflammatory chemokines, and support of cell migration, which are all plausible repair mechanisms. The only Western-standard human trial data for Tb4 is in ophthalmology, where the clinical-stage formulation RGN-259 has run Phase 2 and Phase 3 trials for dry eye disease and neurotrophic keratopathy. A 2026 review of injectable peptide therapies found that Tb4 and the TB-500 fragment promoted angiogenesis and tissue repair in preclinical models, but stated plainly that human orthopaedic data are lacking^[3].

What the 2026 sports medicine literature says overall

A 2026 narrative review in Sports Medicine examining the safety and efficacy of unapproved peptide therapies for musculoskeletal injuries, including both BPC-157 and TB-500, found that while many of these compounds demonstrate favourable tissue repair outcomes in animal models, rigorous human safety data are scarce^[4]. The authors describe these peptides as operating largely outside regulatory oversight and note there is potential for serious harm to patients. A separate 2026 primer for orthopaedic and sports medicine physicians reached the same conclusion: the indications, dosing, frequency, and duration of treatment remain unknown for clinical use^[3].

Regulatory status and supply chain risks

Neither BPC-157 nor TB-500 is authorised as a medicine by the FDA, the EMA, the MHRA, or any national agency we cover. Both appear on the WADA Prohibited List and are banned substances in sport. The US Department of Defense's Operation Supplement Safety programme describes BPC-157 as an unapproved drug with little to no reliable scientific evidence to support its safety or effectiveness in humans^[5]. Products are sold online under labels like 'research use only' or 'not for human consumption', which do not confer legal protection for sellers or safety assurance for buyers.

The supply chain risk is real. Independent testing of grey-market peptide vials has repeatedly found purity and identity failures, including vials containing wrong molecules, low-purity batches sold as high-purity, and endotoxin contamination above pharmaceutical limits. Per-country regulatory detail is on the BPC-157 regulation pages and the TB-500 regulation pages.

What we do not yet know

The honest position on both compounds is that the preclinical data is more interesting than conclusive. We do not know whether the angiogenic and growth-factor effects seen in rodent tendons translate to human tendons at any dose. We do not know a safe human dose range, because no published dose-finding trial in humans exists for either compound. We do not know the long-term consequences of repeated use, including effects on cancer biology given that both compounds act on growth-promoting pathways. And we do not know whether any given vial from a grey-market source contains what it claims.

The FDA's Pharmacy Compounding Advisory Committee was scheduled to review BPC-157's eligibility for compounding under section 503A in July 2026. Whatever that committee recommends, it does not change the underlying unapproved status of the compound or generate the missing clinical trial data.